The Commission has replied to the Ombudsman's findings concerning its refusal to give public access to text messages between its President and the CEO of a pharmaceutical company about a COVID-19 vaccine contract. The Ombudsman's initial analysis is that the reply is problematic on several points. The closing decision, to be published within the coming weeks, will include a full analysis.